Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Avience Biomedicals Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹208
Per ShareLot Size
600 Shares
Minimum Investment
₹1,24,800
Issue Size
₹30.24 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.08%
QIB Quota
49.83%
NII Quota
15.09%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
87.89%
Promoter Holding (Post-Issue)
64.59%
Issue Type
Book Building - SME
ISIN
INE0V9I01017
Recognized under the Make in India Mission initiated by Prime Minister Narendra Modi, The Company commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, HIV, HBs AG, Malaria, Dengue and others aimed at aiding medical institutions with affordable and good quality solutions. Avience Biomedicals has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents, showcasing a dedication to addressing various healthcare needs.
The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. Major segments of Indian Pharmaceutical Industry include diagnostic kits, medical devices etc. The healthcare and medical device sectors in India have grown significantly in the last decade. A wide range of medical devices, from consumables to implantable medical devices, are produced in India. Most medical devices manufactured in India are biochemistry analyser, Reagents, devices related to hematology and immunology etc. The medical devices sector is highly capital intensive and requires continuous training of the healthcare system providers to adapt to new technologies. The Indian laboratory diagnostics industry, estimated at USD 18.5 billion, is growing at a healthy rate of 13-14% per annum. Currently there are more than 1 lakh labs across the country, offering a wide range of tests (up to 4500). The Indian industry operates at one of the lowest price points in the world. The costs are around one-eighth those in the US. Even at these low rates, the Indian medical diagnostics industry has been able to provide people living in remote areas access to modern diagnostics facilities.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public issue of 14,53,800 equity shares of face value of Rs. 10/- each ("The Equity Shares") of Avience Biomedicals Limited ("The Company" or "ABL" or The "Issuer") at an issue price of Rs. 208 per equity share for cash, aggregating to Rs. 30.24 Crores ("Public Issue") out of which 82,200 equity shares of face value of Rs. 10 each, at an issue price of Rs. 208 per equity share for cash, aggregating to Rs. 1.71 Crores will be reserved for subscription by the market maker to the issue (The "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 13,71,600 equity shares of face value of Rs. 10 each, at an issue price of Rs. 208 per equity share for cash, aggregating to Rs. 28.53 Crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.50% and 25.01% respectively of the post-issue paid-up equity share capital of the company. Price Band: Rs. 208/- per equity share of face value Rs. 10/- each. The floor price is 20.8 times the face value of the equity. Bids can be made for a minimum of 600 equity shares and in multiples of 600 equity shares thereafter.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Our Company was incorporated as Avience Biomedicals Private Limited under the provisions of the Companies Act, 2013 vide certificate of incorporation dated December 23, 2019, in Delhi. Subsequently, our Company was converted into a Public Limited Company pursuant to Shareholders Resolution passed at the Extra Ordinary General Meeting of the Company held on June 26, 2024 and the name of our Company was changed from "Avience Biomedicals Private Limited" to "Avience Biomedicals Limited" vide a fresh Certificate of Incorporation dated September 03, 2024 having CIN U74999DL2019PLC359158 issued by the Registrar of Companies, Central Processing Centre, Delhi. The registered office of our company is situated at C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi-110058, India.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.